Equities Analysts Set Expectations for Ascendis Pharma A/S’s Q3 2024 Earnings (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASND) – Stock analysts at Leerink Partnrs dropped their Q3 2024 earnings per share (EPS) estimates for Ascendis Pharma A/S in a research report issued on Monday, September 16th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings of ($1.96) per share for the quarter, down from their previous estimate of $0.85. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($6.83) per share. Leerink Partnrs also issued estimates for Ascendis Pharma A/S’s FY2024 earnings at ($8.38) EPS and FY2026 earnings at $1.48 EPS.

ASND has been the subject of a number of other reports. TD Cowen dropped their price objective on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating for the company in a report on Wednesday, September 4th. Wells Fargo & Company lifted their price target on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a research note on Tuesday. Jefferies Financial Group increased their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. dropped their target price on Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, September 4th. Finally, Oppenheimer reiterated an “outperform” rating and set a $190.00 price target (up from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and an average target price of $193.77.

Ascendis Pharma A/S Price Performance

Shares of Ascendis Pharma A/S stock opened at $148.88 on Thursday. The company has a 50 day simple moving average of $132.71 and a two-hundred day simple moving average of $136.43. The firm has a market cap of $8.67 billion, a PE ratio of -15.49 and a beta of 0.63. Ascendis Pharma A/S has a 1 year low of $85.29 and a 1 year high of $161.00.

Institutional Trading of Ascendis Pharma A/S

Institutional investors have recently modified their holdings of the company. Gilbert & Cook Inc. increased its holdings in Ascendis Pharma A/S by 8.4% during the 4th quarter. Gilbert & Cook Inc. now owns 2,838 shares of the biotechnology company’s stock valued at $357,000 after purchasing an additional 220 shares during the period. Quadrant Capital Group LLC raised its holdings in shares of Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 151 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Ascendis Pharma A/S by 1.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 16,384 shares of the biotechnology company’s stock worth $2,064,000 after acquiring an additional 159 shares during the period. Trexquant Investment LP purchased a new stake in Ascendis Pharma A/S in the fourth quarter worth $1,243,000. Finally, EverSource Wealth Advisors LLC increased its position in Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.